Lapress (Lercanidipine Hydrochloride)

Lapress, a calcium channel blocker, is employed in the management of arterial hypertension.

• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Isolated systolic hypertension: lowers elevated systolic pressure, improving cardiovascular risk profile.
• Hypertensive patients with cardiovascular risk: provides sustained blood pressure control to lower risk of stroke and myocardial infarction.

• Lercanidipine hydrochloride selectively blocks L-type calcium channels in vascular smooth muscle, preventing calcium influx that is required for contraction. This inhibition leads to vasodilation of peripheral arteries, decreasing systemic vascular resistance and ultimately lowering arterial blood pressure without significant effect on heart rate.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially when standing.
• Tachycardia: increased heart rate in some patients.
• Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, itching, or hives.
• Angioedema: swelling of face, lips, or throat.
• Cardiac conduction disturbances: heart block or arrhythmias.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Blood pressure monitoring: check regularly to ensure therapeutic response and avoid excessive hypotension.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Elderly patients: start at the lowest effective dose and monitor for dizziness.
• Concomitant antihypertensives: assess for additive blood pressure‑lowering effects.
• Severe aortic stenosis: contraindicated due to risk of sudden drop in pressure.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Lercanidipine may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension.
• Grapefruit juice: can elevate drug concentration leading to excessive blood pressure reduction.
• Other potent antihypertensives: may cause additive hypotensive effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Diuretics: can enhance electrolyte disturbances.
• NSAIDs: may blunt antihypertensive response.
• Beta‑blockers: combined use may increase risk of bradycardia.